Your session is about to expire
← Back to Search
Chemotherapy for Triple Negative Breast Cancer
Study Summary
This trial is testing if giving carboplatin and nab-paclitaxel before surgery can help treat triple negative breast cancer.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2010 Phase 2 trial • 76 Patients • NCT00404235Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your creatinine levels should be less than or equal to 1.5 mg/dL, but your hospital's normal range may also be accepted.My breast cancer is advanced but not spread to distant parts, and it's triple negative.Women who can become pregnant must have a negative pregnancy test.I have not received any treatment for my newly diagnosed breast cancer and had no taxanes or carboplatin for any past cancer treated over 5 years ago.Your AST and ALT levels should not be more than twice the upper limit of normal.Your heart is pumping blood normally.Your white blood cell count is at least 1,500 cells per cubic millimeter.My neuropathy is mild or I don't have it.My tumor does not show hormone receptors and is HER2 negative.Your platelet count is at least 100,000 cells per cubic millimeter.Your bilirubin level should be less than or equal to 1.5 mg/dL.I have an active HIV infection.I was treated for breast cancer or another cancer within the last 5 years.Your alkaline phosphatase level is not more than twice the upper normal limit.Your hemoglobin level is higher than 9.0 grams per deciliter.You have an ongoing hepatitis B or C infection.
- Group 1: Treatment (carboplatin and nab-paclitaxel)
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the paclitaxel albumin-stabilized nanoparticle formulation been given authorization by the FDA?
"The safety of paclitaxel albumin-stabilized nanoparticle formulation was rated a 2, as there is only evidence to suggest it is safe but not that it is effective in treating diseases."
What types of maladies can be remedied by paclitaxel albumin-stabilized nanoparticle formulation?
"Paclitaxel albumin-stabilized nanoparticle formulation is a popular intervention for neoplasm metastasis. However, this advanced treatment modality has also been employed to address acute pyelonephritis (APN), lymphoma, non-Hodgkin's shock and hypovolemic conditions."
Are there any vacancies for enrolment in this experiment?
"Per the clinicaltrials.gov records, this specific medical trial is not presently enrolling any participants. Having first been posted on February 15th 2012 and most recently edited on July 9th 2021, there are no longer openings available for applications; however, 3465 other trials have open spots right now."
What is the total number of people participating in this experiment?
"This trial is no longer recruiting patients; it was initially posted on February 15th 2012 and its data most recently updated on July 9th 2021. For those looking for other studies, 2358 clinical trials are currently searching for individuals with Stage IIIA breast cancer while 1,107 separate medical experiments are bringing in participants to test paclitaxel albumin-stabilized nanoparticle formulation."
Share this study with friends
Copy Link
Messenger